The effect of vasopressin on pulmonary vascular resistance in septic shock
Summary description of the study
Intensive care patients with septic shock often require high doses of circulatory support medications (typically norepinephrine) to stabilize systemic blood pressure. As undesirable side effects, impairments in pulmonary circulation may occur (right heart problems, increased resistance in the pulmonary vessels). Vasopressin is another medication approved for the treatment of septic shock. Interestingly, there seem to be no receptors in the pulmonary circulation where vasopressin can act, unlike norepinephrine. Therefore, the aforementioned norepinephrine-associated problems may occur less frequently when vasopressin is administered simultaneously, allowing for a reduction in the norepinephrine dose. This prospective project will examine, according to a well-defined protocol, how pulmonary circulation changes with the use of vasopressin in patients with septic shock. We hypothesize that resistance in the pulmonary vessels does not increase or even decreases with the simultaneous use of vasopressin, which would be beneficial for right heart function.
(BASEC)
Intervention under investigation
The effect of vasopressin on resistance in the pulmonary vessels in patients with septic shock will be investigated.
(BASEC)
Disease under investigation
Severely ill patients with septic shock, who are treated in the intensive care unit, will be studied.
(BASEC)
- Age 18-80 years - Septic shock - Stable norepinephrine dose (greater than 0.3 mcg/kg/min) with norepinephrine as the only blood pressure-supporting medication (BASEC)
Exclusion criteria
- Known pulmonary hypertension - Chronic obstructive pulmonary disease grade IV - Acute pulmonary embolism (BASEC)
Trial sites
Zurich
(BASEC)
Sponsor
Prof. Dr. med. Sascha David Universitätsspital Zürich – Institut für Intensivmedizin Rämistrasse 100 CH-8091 Zurich
(BASEC)
Contact
Contact Person Switzerland
PD Dr. med. Daniel Hofmänner
+41 43 253 07 37
danielandrea.hofmaenner@clutterusz.chUniversity Hospital Zurich Institute of Intensive Care Medicine
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee Zurich
(BASEC)
Date of authorisation
10.12.2024
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
The Effect of Vasopressin on Pulmonary Vascular Resistance in Septic Shock (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available